Emerging Targets for Sarcoma Therapy
转载请注明来自丁香园
Results from Phase 1 Trial of IPI-504,a Novel HSP90 Inhibitor,in Tyrosine Kinase Inhibitor -Resistant GIST and other arcomas
Safety,pharmacokinetics and preliminary activity of the anti-IGFR-IR antibody CP-751,871 in patients with sarcoma
作者: 丁香园通讯员
以下网友留言只代表网友个人观点,不代表网站观点 | |||
Copyright 2000-2025 DXY.CN All Rights Reserved